secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001140361-24-020320
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma awards director Dr. Pepose $39,583/mo consulting fee, 32K RSUs and 48K options at $1.79
--------------------------------------------------------------------------------

- Monthly consulting fee of $39,583 for Dr. Jay Pepose, an existing director, effective April 11, 2024.
- Grant of 32,000 restricted stock units vesting on April 11, 2025, subject to continued service.
- Options to purchase 48,000 shares at $1.79 (closing price on grant date), vesting in 12 monthly installments.
- Agreement terminates on April 11, 2025, unless extended by mutual written agreement.
- Consulting services in the field of ophthalmology; Dr. Pepose remains an independent contractor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124020320/0001140361-24-020320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124020320/ef20027138_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-020320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer